Clinical Trial Update: Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating the combination of pirtobrutinib with venetoclax in relapsed/refractory mantle cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Mantle Cell Lymphoma, Non Hodgkin Lymphoma | Phase 2 | Status: RECRUITING